 |
 |
Clay B. Siegall, Ph.D.,
co-founded Seattle Genetics in 1998 and is the company’s
President, Chief Executive Officer and Chairman of the
Board of Directors. Under his leadership, Seattle
Genetics has built a diverse portfolio of clinical and
preclinical antibody-based therapies for the treatment
of cancer and autoimmune disease. The company has also
developed proprietary technologies for empowering
antibodies, including its industry-leading antibody-drug
conjugate (ADC) technology and its novel SEA technology.
Dr. Siegall has guided Seattle Genetics’ capital-raising
activities, securing more than $500 million through
public and private financings, including the company’s
initial public offering in 2001. In addition, the
company has entered into multiple strategic
collaborations, including with Millennium: The Takeda
Oncology Company, Genentech (Roche), Bayer,
MedImmune (AstraZeneca), Agensys (Astellas) and Daiichi
Sankyo.
Prior to co-founding Seattle Genetics, Dr. Siegall was
with the Bristol-Myers Squibb Pharmaceutical Research
Institute from 1991 to 1997 and the National Cancer
Institute, National Institutes of Health from 1988 to
1991. He serves on the Board of Directors of Alder
BioPharmaceuticals, a private biotechnology company. Dr. Siegall is an author on more than 70
publications and holds 15 patents. He received a Ph.D.
in Genetics from George Washington University and a B.S.
in Zoology from the University of Maryland.
Srinivas Akkaraju, M.D., Ph.D., has served as a Director of Seattle Genetics since July 2003. Dr. Akkaraju is a Managing Director and lead of New Leaf Venture Partners' West Coast biopharmaceuticals practice. Previously, he served as a Managing Director at Panorama Capital. Before that, he was with J.P. Morgan Partners, serving as a Principal starting in April 2001 and becoming a Partner in January 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc., most recently as Senior Manager. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he earned his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. He is also a director of Barrier Therapeutics.
Felix J. Baker, Ph.D., has served as a Director of Seattle Genetics since July 2003 and as Lead Director since February 2005. Dr. Baker is a Managing Member of Baker Brothers Advisors, LLC, which he and his brother, Julian Baker, founded in 2000. Dr. Baker's firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations that are focused on publicly traded life sciences companies. His career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. in Biology and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He is also a director of Trimeris and Conjuchem, both of which are publicly traded biotechnology companies.
Franklin M. Berger, CFA, has served as a Director of Seattle Genetics since June 2004 and is Chairman of the Audit Committee. Mr. Berger is a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. He served most recently as Managing Director, Equity Research and Senior Biotechnology Analyst at J.P. Morgan Securities from 1998 to 2003. In this position, he initiated team coverage of 26 biotechnology companies and was responsible for technical, scientific and clinical due diligence as well as company selection. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney from 1997 to 1998 and Josephthal & Co. from 1991 to 1997. Prior to his work as a biotechnology analyst, he managed Pantagruel Partners, a firm that developed early-stage pharmaceutical compounds for sale to drug companies and venture capital firms. He holds an M.B.A. from the Harvard Graduate School of Business Administration and an M.A. in International Economics and a B.A. in International Relations from Johns Hopkins University. In addition to Seattle Genetics, Mr. Berger serves as a director of VaxGen, Inc., Isotechnika Inc. and Thallion Pharmaceuticals, all publicly-traded biopharmaceutical companies, and HealthShares, Inc., an investment company.
David W. Gryska joined our Board of Directors in March 2005. Since December 2006, Mr. Gryska has been Senior Vice President and Chief Financial Officer of Celgene. Previously, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. From 1998 to 2004, Mr. Gryska was Senior Vice President and Chief Financial Officer at Scios, Inc., where he led the transaction effort for the successful sale of the company to Johnson & Johnson for $2.5 billion in February 2003. From 1993 to 1998, he served as Vice President and Chief Financial Officer at Cardiac Pathways, a company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. He holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University.
Daniel F. Hoth, M.D., joined our Board of Directors in March 2006. He is President of Hoth Consulting, where he provides drug development and clinical trial consulting services to pharmaceutical and biotechnology companies. Previously, Dr. Hoth served as Senior Vice President and Chief Medical Officer of Axys Pharmaceuticals (now Celera Genomics) and Cell Genesys. From 1981 to 1993, he held various positions at the National Institutes of Health (NIH), including Director, Division of AIDS at the National Institute of Allergy and Infectious Diseases, and Chief of the Investigational Drug Branch of the National Cancer Institute. Before the NIH, he was on the faculty of the Georgetown University School of Medicine. Dr. Hoth received his M.D. from Georgetown University School of Medicine and A.B. in Psychology from Franklin and Marshall College.
Marc E. Lippman, M.D., has served as a Director of Seattle Genetics since June 2000. In May 2007, Dr. Lippman was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and Chairman of the Department of Medicine. Previously, he served as the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Before that, Dr. Lippman was the Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, and Professor of Medicine at Georgetown University Medical School. He was also Chief of the Division of Hematology-Oncology and served as Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute. Dr. Lippman has received the Clinical Investigator Prize of the American Federation for Clinical Research, the Rosenthal Award of the American Association for Cancer Research, the American Cancer Society Lectureship awarded by the American Society for Clinical Oncology, the Astwood Prize of the Endocrine Society, and the Brinker International Prize for Basic Research in Breast Cancer. He has published over 400 peer-reviewed articles. In addition, he has authored several books and contributed many chapters based on his breast cancer research, including a textbook on breast disease. Dr. Lippman received his B.A., magna cum laude from Cornell and his M.D. from Yale where he was elected to Alpha Omega Alpha.
John P. McLaughlin has served as a Director since June 2007. In December 2008, Mr. McLaughlin was appointed President and Chief Executive Officer of PDL BioPharma. From 2000 to 2008, he was Chief Executive Officer and a member of the Board of Directors of Anesiva, Inc. Prior to Anesiva, he was President of Tularik, and before that he spent 11 years at Genentech in a number of senior management positions including Executive Vice President and General Counsel. Previously, Mr. McLaughlin represented major pharmaceutical companies as a partner in a Washington, D.C. law firm that specializes in food and drug law and served as legal counsel to various subcommittees in the U.S. House of Representatives, drafting numerous measures that became U.S. Food and Drug Administration laws. Mr. McLaughlin is a co-founder and director of Peak Surgical. He was also co-founder and Chairman of Eyetech Pharmaceuticals, which was acquired by OSI Pharmaceuticals in 2005, and a director of IDEC Pharmaceuticals. He earned a B.A. in Government from the University of Notre Dame and a J.D. from the Catholic University of America.
Daniel G. Welch has served as a Director since June 2007. Since September 2003, Mr. Welch has been Chief Executive Officer and President of Intermune, a biotechnology company focused on treatments for pulmonary and hepatic diseases, and has been its Chairman of the Board since May 2008. Before joining Intermune, he was Chairman and Chief Executive Officer of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Prior to that, he was President of Biopharmaceuticals at Elan Corporation. During his tenure at Elan he was responsible for its U.S. commercial operations, international subsidiaries, R&D and diagnostics businesses. From 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo, now Sanofi-Aventis, including Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business. Mr. Welch holds a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.